Carboplatin versus cisplatin in solid tumors: An analysis of the literature

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 13-21

  Lokich, J ^a   Anderson, N ^b  

^a Cancer Center   (United States)

^b NONE

Author keywords

Carboplatin; Cisplatin; Randomized trials

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; NAVELBINE; NITROSOUREA DERIVATIVE; PACLITAXEL; TOPOTECAN; VINBLASTINE; VINCRISTINE; VINDESINE;

AREA UNDER THE CURVE; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MEDICAL LITERATURE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER NEOPLASMS;

EID: 6844222840     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008215213739     Document Type: Review

References (53)

1. Horwich A. Carboplatin in the treatment of testicular cancer: The Royal Marsden Hospital Testicular Tumour Unit Experience. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 53-62.
2. Kavanagh JJ. Carboplatin in refractory epithelial ovarian cancer. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 141-6.
3. Trump DL, Elson P, Madajewicz S. A phase II trial of carboplatin in advanced transitional cell carcinoma of the urothelium. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 93-7.
4. Smith IE. Carboplatin in small-cell lung cancer: The Royal Marsden Hospital experience. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 243-7.
5. Green M, Kretsman H, Lutkart S et al. Carboplatin in non-small-cell lung cancer: The Cancer and Leukemia Group B experience. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 301-6.
6. Volling P, Schroeder M, Achterrath W. Phase II trial with carboplatin and 5-fluorouracil in previously untreated patients with advanced squamous cell carcinoma of the head and neck. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 213-9
7. Raghavan D, Gianoutsos P, Bishop J et al. Phase II trial of carboplatin in the treatment of advanced malignant mesothelioma. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 341-4.
8. Martinez JA, Morton G, Sanz GF et al. A phase II clinical trial of carboplatin infusion in high risk acute non lymphoblastic leukemia. J Clin Oncol 1991; 9: 39.
9. Lee E and Van Echo DA. The potential of carboplatin in human leukemia. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia: W.B. Saunders Company 1990; 361-5.
10. Ruckdeschel JC. The future role of carboplatin. Semin Oncol 1994; 21: 114-8.
11. Comis RL. Cisplatin: The future. Semin Oncol 1994; 21: 109-13.
12. Weed DL. Methodologic guidelines for review papers. J Natl Cancer Inst 1997; 89(1).
13. Knox RJ, Friedlos F, Lydall DA et al. Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diam-minedichloroplatinum (II) and cis-diammine(1,1-cyclobutane-diacarboxylate) platinum (II) differ only in kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972-9.
14. Reed E, Dabholkar M, Chabner BA. In Chabner A and Longo D (eds): Platinum Analogues in Cancer Chemotherapy and Biotherapy. 2nd Edition. Philadelphia: Lippincott-Raven Publishers 1996.
15. Calvert AH, Newell DR, Grumbrell LA et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
16. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-8.
17. Van der Vijgh VJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242-61.
18. Trump DL, Grem JL, Tutsch KD et al. Platinum analogue combination chemotherapy: Cisplatin and carboplatin - a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol 1987; 5: 1281-9.
19. Patton JF, Powell BL, White DR et al. Combination cisplatin and carboplatin in advanced squamous cell carcinoma of the head and neck. Cancer Invest 1996; 14(2): 98-102.
20. Piccart MJ, Nogaret JM, Marcelis L et al. Cisplatin combined with carboplatin: A new way of intensification of platinum dose in the treatment of advanced ovarian cancer. J Natl Cancer Inst 1990; 82 (8): 703-7.
21. Taylor AE, Wiltshaw E, Gore ME et al. Long-term follow up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994; 12: 2066-70.
22. Adams M, Kerby U, Rocker I et al. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynacological Cancer Group. Acta Oncol 1989; 28(1): 57-60.
23. Mangioni C, Bolis G, Pecorelli S et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81: 1464-71.
24. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10: 718-26.
25. Ten Bokkel Huinink WW, Van der Burg MEL, Van Oosterom AT et al. Carboplatin combination therapy for ovarian cancer. Cancer Treat Rep 1988; 15 (8): 9-15.
26. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide. Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-17.
27. Conte PF, Bruzzone M, Carmino F et al. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide. A randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1991; 9: 658-63.
28. Belpomme D, Bugat R, Rives M et al. Carboplatin versus cisplatin in association with cyclophosphamide and doxorubicin as first line therapy in stage III-IV ovarian carcinoma: Results of an ARTAC phase III trial. Proc ASCO 1992; 11: 227.
29. Edmonson JH, McCormack GM, Wieand HS et al. Cyclophosphamide-cisplatin versus cyclophosphamide carboplatin in myelosuppressive regimens. J Natl Cancer Inst 1989; 81: 1500-4.
30. Neijt JP, Hansen M, Hansen PG et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc ASCO 1997; 16: 352a.
31. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. BMJ 1991; 303: 884-93.
32. Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA et al. Advanced ovarian cancer. Carboplatin versus cisplatin. Ann Oncol 1993; 4 (Suppl 4): 41-8 (Review).
33. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-11.
34. Repetto L, Chiara S, Mammoliti S et al. Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecol Oncol 1990; 39: 146-9.
35. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5.
36. McGuire WP, Hopkins WJ, Brady ME et al. Cyclosphosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
37. Kohn EC, Sarosy GA, Davis P et al. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol 1996; 62: 181-91.
38. Markman M. Carboplatin and cisplatin: Are they equivalent in efficacy in 'optimal residual' advanced ovarian cancer? J Cancer Res Clin Oncol 1996; 122: 443-4.
39. De Andres L, Brunet J, Lopez-Pousa A et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-MO Head and Neck cancer. J Clin Oncol 1995; 13: 1493-500.
40. Forestiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A southwest Oncology Group Study. J Clin Oncol 1992; 10: 1245-251.
41. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A ran-domized phase II study. Cancer 1996; 77 (2): 344-51.
42. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 1993; 11: 598-606.
43. Bokemeyer C, Kohrmann O, Tischler L et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7: 1015-21.
44. Bliss J, Horwich A. Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours. Ann Oncol 1996; 7: 989-91 (Editorial).
45. Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional medical research council/European organization for research and treatment of cancer trial. J Clin Oncol 1997; 15: 1844-52.
46. Skalos DV, Samantas E, Kosmidis P et al. Randomized comparision of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 1994; 5: 601-7.
47. Klastersky J, Sculier JP, Lacroix G et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556-62.
48. Kaye SB, Lewis CR, Paul J et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33.
49. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996; 14: 2113-9.
50. Conte PF, Bruzzone M, Carnino F et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996; 14: 351-6.
51. Thigpen JT. Dose-intensity in ovarian carcinoma: Hold, enough? J Clin Oncol 1997; 15: 1291-3 (Editorial).
52. Bertelsen JK, Anderson JE, Havsteen H et al. Dose-effect study of carboplatin in ovarian cancer: A Danish ovarian cancer group study. J Clin Oncol 1997; 15: 193-8.
53. Alberts D. Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis. Phar Ther July 1994.